Overview

Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt)

Status:
Completed
Trial end date:
2018-11-28
Target enrollment:
Participant gender:
Summary
The study will assess the bioequivalence between single doses of GXR manufactured in Merck Nantong China (test drug) and GXR manufactured in Merck Darmstadt Germany (reference drug) under fed and fasted state in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Metformin